TELA Bio (NASDAQ:TELA) Posts Earnings Results, Misses Expectations By $0.07 EPS

TELA Bio (NASDAQ:TELA) announced its quarterly earnings results on Tuesday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07), Zacks reports. TELA Bio had a negative return on equity of 433.58% and a negative net margin of 48.37%.The company had revenue of $19.06 million during the quarter, compared to the consensus estimate of $18.60 million.

Here are the key takeaways from TELA Bio’s conference call:

• Management said the U.S. commercial reset is showing early proof points, with the field force now fully staffed and new hires ramping toward expected productivity inflection points in the second half of 2026.
• TELA launched OviTex LTR in the U.S., a fully resorbable tissue-based hernia repair option, and said early surgeon feedback has been overwhelmingly positive. The company believes it broadens the portfolio and could help attract new surgeons.
• International momentum was strong, with Europe revenue up 41% year over year, led by the U.K. and supported by validation from the NHS supply chain value-based procurement evaluation.
• First-quarter revenue rose 3% to $19.1 million, while gross margin was 66% and operating loss was flat year over year at $10.5 million. The company reiterated full-year 2026 guidance for at least 8% revenue growth and Q2 revenue of about $20 million.
• OviTex PRS revenue was essentially flat year over year, and management said utilization dipped because several high-volume implanters were unavailable. The company is trying to reduce this concentration risk by training more surgeons per account.

TELA Bio Stock Performance

TELA opened at $1.02 on Wednesday. The company has a current ratio of 4.20, a quick ratio of 3.59 and a debt-to-equity ratio of 8.82. The company has a market cap of $45.67 million, a price-to-earnings ratio of -1.23 and a beta of 1.30. The company’s 50 day moving average is $0.76 and its 200 day moving average is $0.96. TELA Bio has a 12-month low of $0.50 and a 12-month high of $2.20.

Hedge Funds Weigh In On TELA Bio

A number of institutional investors and hedge funds have recently made changes to their positions in TELA. Susquehanna International Group LLP boosted its holdings in shares of TELA Bio by 551.2% in the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after buying an additional 72,594 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in TELA Bio by 101.4% during the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after purchasing an additional 64,800 shares in the last quarter. XTX Topco Ltd purchased a new position in TELA Bio during the fourth quarter valued at approximately $48,000. Finally, Citadel Advisors LLC lifted its holdings in TELA Bio by 161.3% during the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after purchasing an additional 21,781 shares in the last quarter. Hedge funds and other institutional investors own 94.35% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Piper Sandler reduced their price target on shares of TELA Bio from $1.25 to $1.00 and set a “neutral” rating for the company in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a research note on Tuesday, April 21st. Lake Street Capital reduced their price target on shares of TELA Bio from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Canaccord Genuity Group reduced their price target on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Finally, Citizens Jmp reduced their price target on shares of TELA Bio from $5.00 to $3.00 and set a “market outperform” rating for the company in a research note on Friday, March 27th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, TELA Bio has an average rating of “Hold” and a consensus target price of $2.20.

TELA Bio Company Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.